Blockbuster Weight loss shots can lower migraine days in two for millions of patients, suggests a study.
Researchers in Italy gave 31 obese adults suffering from chronic or frequent migraine liraglutide, the active ingredient in weight loss medicines Victoza and Saxenda.
After three months, the average number of migraine days fell from the participants from 20 to 11.
They also said that their migraine was less invalidating, which means that they could function better at work, school, social institutions or around the house.
Although the participants lost a small amount of weight that has been shown to reduce the migraine frequency by reducing inflammation and muscle tension, weight loss is probably not what reduced migraine is.
The researchers believe that liraglutide pressure illuminates by cerebrospinal liquid, the protective liquid that dampens the brain and spine.
Dr. Simone Braca, head study author and neurologist at the University of Naples Federico II, suggests that even small structure of cerebrospinal fluid can insist on veins and nerves in the brain that can cause migraine.
He suggested focusing on the levels of cerebrospinal liquid, migraine could make a thing of the 47 million Americans who suffer from them.
Researchers in Italy found that Liraglutide, the active ingredient in weight loss drugs Victoza and Saxenda, migraine frequency can be reduced by 50 percent (stock image))
The graph above shows the average number of migraine days before and after the participants started with liraglutide
Dr. Brac told ABC News: ‘An increased pressure from the spinal cord fluid in the brain can be one of the migraine underlying the underlying migraine.
“And if we focus on this mechanism, this suggests provisional evidence that it can be useful for migraine.”
Migraine are a severe form of headache that causes throbbing, pulsating pain, usually on one side of the head.
These can last hours or days at the same time and are activated by stress, hormonal fluctuations, sleeping problems, foods or drinks, scents, lights, noise and weather changes, among other things.
About one in seven Americans suffers migraine, but for women that number is closer to one in five. This can be due to hormones such as estrogen and menstrual cycles, as well as certain genes that increase sensitivity.
In the meantime, about one in eight Americans, or 40 million, has reported a GLP -1 agonist such as Victoza or Ozempic at a certain moment -who uses Semaglutide as the active ingredient instead of liraglutide.
The new study, published earlier this month in the magazine HeadacheLooked at 31 obese adults who had or were diagnosed with chronic migraine at least eight days a month.
Chronic migraine, which influences around 4 million Americans, is defined as at least 15 headache days in a month.
Participants in the study also had to have failed at least two standard migraine drugs and have a Body Mass Index (BMI) of at least 30, the threshold for obesity.
The vast majority, 26, was female and the average age of the participants was 45.
They received a week a week of 0.6 milligrams of dose of liraglutide and then a 1.2 milligram dose every day during the rest of the four weeks. All participants were asked to stay on their current migraine medicines when they took them.
With the help of the self-absorbed symptom of the ‘diaries’, the researchers discovered that 15 patients had at least a reduction in migraine frequency by 50 percent
Seven participants (23 percent) saw their migraine fall by 75 percent and one patient had no headache at all after the study.
On average, migraine days fell from 20 to 11, a difference of 42 percent.
About one in eight Americans, or 40 million, has reported that he has taken a GLP-1 agonist such as Victoza or Ozempic (depicted here)
The team has also measured the migraine rating score of each patient (Midas), which determines how much their migraine can eliminate them and can make them less functional at work, school or at home on a certain day.
A higher score is associated with a larger handicap.
The researchers discovered that Midas scores fell on average 60 to 29, a difference of 52 percent.
Participants lost a small amount of weight on average, but it was not statistically significant.
About 42 percent of the participants (13) had mild side effects, including nausea and constipation, but they all stayed with the medication.
There were various restrictions on the study, such as the small sample size and the lack of data on glucose or A1C levels, which are linked to diabetes.
The team wrote: “Future studies, with extensive follow-up duration and higher dose evaluations, are necessary to better understand the tolerability and effectiveness of liraglutide in migraine prevention.”
#newest #shocking #Ozempian #side #effect #revealed #lives #people